Ipsen has become the newest entrant in the antibody-drug conjugate (ADC) race, handing over around $90 million in near-term payments to Sutro Biopharma in return for the global rights to a preclinical candidate. The asset in question, dubbed STRO-003, targets the receptor tyrosine kinase-like orphan receptor 1 (ROR1) tumor antigen. Source: Fierce Biotech 2/4/2024